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Abbreviations: 
SSc: systemic sclerosis, scleroderma 
PAH: pulmonary arterial hypertension 
PAP: pulmonary artery pressure 
ILD: interstitial lung disease 
LV: left ventricle 
LA- left atrium 
ECM: extracellular matrix 
TGF-β Transforming growth factor beta  
ET- 1 endothelin one 
CTGF- connective tissue growth factor  
PDGF -  Platelet-derived growth factor  
RHC- right heart catheterization  
mPAP - mean pulmonary arterial pressure  
ACR- American College of Rheumatology  
EULAR- European League Against Rheumatism  
PCWP - pulmonary capillary wedge pressure  
PVR- pulmonary vascular resistance  
NYHA- New York Heart Association  
TDI: Tissue Doppler Imaging 
RV- right ventricle  
RVOT- Right ventricular outflow tract  
TAPSE- Tricuspid Annular Plane Systolic Excursion  
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PASP- estimated pulmonary systolic pressure   
TRV- tricuspid Doppler Tracing  
EDE - Exercise Doppler Echocardiography  
CO- cardiac output  
CI- cardiac index 
WU - Wood Units 
DLCO- diffusing capacity of the lungs for carbon monoxide 
STE- two-dimensional speckle tracking strain echocardiography   
BSA - body surface area  
ε pos peak- positive peak left atrial longitudinal strain   
sec ε pos peak- second positive peak left atrial longitudinal strain 
 ε neg peak – negative peak left atrial longitudinal strain 
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1. Background 
Systemic sclerosis (SSc; scleroderma) is a heterogeneous, systemic, autoimmune 
disease. The pathogenesis of SSc is characterized by 3 hallmarks: small vessel 
vasculopathy, production of auto-antibodies and fibroblast dysfunction leading to 
increased deposition of extracellular matrix (ECM)
1
. The clinical manifestations and 
the prognosis of SSc vary with the majority of patients having skin thickening and 
variable involvement of internal organs. Organ manifestations of SSc can be 
particularly problematic when present in the lungs, kidneys or heart.  
The majority of patients with SSc are believed to have subclinical cardiac 
involvement 
2
 
3
 
4
. Overt cardiac manifestations of SSc are associated with poor 
prognosis 
5, 6, 7, 8, and they can be difficult to manage 9.  
Pulmonary arterial hypertension (PAH) is also a frequent complication of SSc and is 
one of the leading causes of morbidity and mortality in patients with this disease
10 11 
12
.  SSc–related PAH is the result of an isolated pulmonary arteriopathy, but in these 
patients, elevated pulmonary artery pressure (PAP) may occur also as a consequence 
of interstitial lung disease (ILD) or left ventricular (LV) systolic and/or diastolic 
dysfunction. 
The thesis is focused on the early detection of cardiac and pulmonary manifestations 
of SSc using different echocardiographic modalities. 
 
1.1 Immunological and pathophysiological background of SSc 
 
The precise etiology of SSc is an expanding area of research, since the accurate 
nature of the mechanisms underlying this disease remains unclear 
13
. The disease 
may be initiated in the vascular bed of the organs, the evidence suggesting that some 
pathomorphological changes may be apparent before the onset of the disease  
13
. The 
pathological events in SSc may include impaired communication between 
endothelial cells, epithelial cells and fibroblasts; lymphocyte activation; autoantibody 
production; inflammation; and connective tissue fibrosis 
13
. These events result in an 
accumulation of constituents of the ECM, which replaces the normal tissue 
architecture, and it can turn into the culmination of organ failure. 
It has been widely recognized that the tissue fibrosis seen in scleroderma patients is 
the end result of a complex biologic process involving immune activation and 
9 
 
vascular injury 
14
.  Clinical and biological evidence suggests that the primary target 
for both initiating and propagating the disease is the epithelium of blood vessels. 
Following tissue injury, the epithelium plays an essential role in repairing wounds 
and re-surfacing tissue. In patients with SSc, there is evidence that this regeneration 
may be dysregulated. Epithelium-derived factors influence the behavior of 
fibroblasts 
15
 
16
  (Table 1). Epithelial to mesenchymal transdifferentiation occurs in 
lung fibrosis, and this process is known to be influenced or mediated by transforming 
growth factor beta  (TGF-β), and potentially endothelin-1 (ET-1) 17 18  19.  
 
             Mediator             Role in fibrogenesis 
TGF-β ECM production, fibroblast proliferation and 
differentiation 
CTGF Regulation of fibroblast proliferation and 
migration and TGF-β- dependent ECM 
synthesis 
ET-1 Regulation of ECM synthesis and contraction 
Fibroblast 
growth factor 
Regulation of fibroblast growth 
IL-1 Inflammatory mediator 
IL-4 Regulation of collagen synthesis 
IL-6 Regulation of α-SMA expression in 
myofibroblasts 
IL-12 Regulation of collagen synthesis 
IL-13 Induction of TGF-β 
IL-17 Fibroblast proliferation 
MCP-1 Inflammatory mediator and regulation of 
collagen synthesis 
MCP-3 Regulation of collagen synthesis 
PDGF Regulation of TGF receptor expression, and 
fibroblast and progenitor cell recruitment 
 
Table 1 Key cytokines in the induction of fibrosis of SSc (from Abraham DJ et al 
Overview of pathogenesis of systemic sclerosis Rheumatology 2009 20)  
 
Fibroblasts maintain the structural integrity of connective tissue, secreting fibrillar 
procollagens, fibronectin and regulating the turnover and composition of the ECM 
via highly specific proteases such as collagenase.  In SSc patients, activated 
fibroblasts are responsible for the development of fibrosis and accumulation of ECM 
molecules. These fibroblasts are characterized by an overproduction of collagen and 
the induction of collagen-modifying enzymes. Fibroblasts can be activated by 
different mechanisms, including direct cell–cell contact, stimulation by soluble 
mediators following induction of the appropriate receptor expression including TGF- 
10 
 
β, connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF) or 
ET-1 
21
 
22
, or by modulation of cell–matrix interactions (Figure 1). 
 
 
 
Figure 1 The role of fibroblasts in the pathogenesis of SSc (D. J. Abraham et al Overview 
of pathogenesis of systemic sclerosis Rheumatology 2009 20) 
 
The immune system also plays a role in the pathology of SSc. Activated 
lymphocytes, auto-antibodies, chemokines, interleukins are detectable in both the 
circulation and the affected organs of SSc patients.  The majority of patients with 
SSc reveal circulating levels of highly specific auto-antibodies: one auto-antibody 
group is directed against nuclear antigens (topoisomerase, RNA polymerase), others 
may have a supposed pathogenic role. This latter group includes anti-endothelial cell 
antibodies, which are estimated to occur in 44–84% of SSc patients and may induce 
apoptosis 
23 24 25 26.  In patients with SSc, vascular remodeling is dysregulated. 
Vasculopathy may result from a disrupted or inappropriate repair process following 
endothelial cell insult or injury. These patients may exhibit up-regulation of 
vasoconstrictive, thrombogenic, mitogenic and pro-inflammatory factors, and down-
regulation of vasodilatatory, anti-thrombogenic and anti-mitogenic factors. These 
results in vasculopathy are characterized by vasoconstriction, adventitial and intimal 
proliferation, inflammation and thrombosis. Vasculopathy involves all layers of the 
vessel wall and is characterized by fibrotic intimal hyperplasia 
27
. As a result, vessels 
11 
 
lose their elasticity and become narrower. In time, the arterial intima may thicken 
and occlusion of the small arteries can facilitate the formation of in situ thrombosis. 
Fibrosis typically begins in the media of medium-sized arteries extending into the 
intima and adventitia and disrupting elasticity. The typical plexiform lesions of 
pulmonary arterial hypertension comprising endothelial cells and myofibroblasts can 
occur at all stages of development and healing 
20
. 
Vascular remodeling appears to be preceded by endothelial dysfunction. Consistent 
evidence suggests that microvascular endothelial cell activation and damage is 
ubiquitous and occurs early in SSc 
20
.   
The possible triggers of endothelial cell activation are: 
  - cross-reactivity between cytomegalovirus epitopes 
    - presence of anti-endothelial cell antibodies 
    - oxidative stress and the presence of elevated levels of reactive oxygen species.  
The primary cause of the initial activation results in endothelial cell damage. 
Apoptosis is an early event, and if endothelial cells are not replaced by new cells, 
capillary breakdown and the typical clinical manifestations of vasculopathy can 
develop. A physiological reaction pattern to capillary breakdown and resulting tissue 
hypoxia is angiogenesis, a finely balanced process involving both angiogenic and 
angiostatic factors. In patients with SSc, angiogenesis becomes dysregulated 
20
.  
ET-1 is a potent and important mediator of vasculopathy. It is a highly potent 
vasoconstrictor that is produced by endothelial cells and is a key mediator of 
vasculopathy, which also promotes cell growth, arterial wall thickening and 
endothelial cell dysfunction resulting in decreased levels of nitric oxide. Moreover, it 
can stimulate the proliferation of pulmonary artery smooth muscle cells and 
fibroblast collagen production 
28 29. Increased ET-1 production can trigger an 
inflammatory cascade elevating the plasma levels of pro-inflammatory cytokines in 
patients with pulmonary arterial hypertension 
30
. Thus, ET-1 promotes 
vasoconstriction and contributes to cardiac and vascular hypertrophy, inflammation 
and fibrosis 
31
. It is over-expressed in both early- and late-stage SSc 
13
. A role in the 
pathogenesis of SSc is also suggested by the finding that circulating levels of ET-1 
correlate with skin fibrosis and the duration of disease 
32
.  
 
 
 
12 
 
1.2 Clinical manifestations and classification of SSc 
 
The diagnosis of SSc was established according to the classification of American 
Rheumatism Association 
33
. However, due to the insufficient sensitivity of the 1980 
criteria and advances in knowledge about SSc, the American College of 
Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
established a committee to provide new classification criteria for SSc 
34
.  
The keystones of recent criteria are:  
-     including broader spectrum of SSc, these are patients whose disease is in an   
          early  stage as  well as those in late stages 
- including vascular, immunologic, and fibrotic manifestations 
- adapted to daily clinical practice usage  
The score system classification criteria based on symptoms and clinical findings are 
shown in Table 2. 
 
        Item Sub-item(s) Weight/score       
Skin thickening of the 
fingers on both hands 
extending proximal to 
the metacarpo-
phalangeal joints 
(sufficient criterion) 
- 9 
Skin thickening of the 
fingers (only count the 
higher score) 
Puffy fingers 
Sclerodactylity 
of the fingers 
(distal to the 
metacarpo-
phalangeal 
joints but 
proximal to the 
proximal 
interphalangeal 
joints) 
2 
4 
Fingertip lesions (only 
count the higher score) 
Digital tip 
ulcers 
Fingertip 
pitting scars 
2 
3 
Telangiectasia - 2 
Abnormal nailfold 
capillaries 
- 2 
Pulmonary arterial 
hypertension and/or 
Pulmonary 
arterial 
2 
2 
13 
 
interstitial lung disease 
(maximum score is 2) 
hypertension 
Interstitial lung 
disease 
Raynaud’s phenomenon - 3 
SSc-related 
autoantibodies 
(anticentromereanti-
topoisomerase I (anti-
Scl-70), anti-RNA 
polymerase III) 
(maximum score is 3) 
Anticentromere 
Anti-
topoisomerase 
I 
Anti-RNA 
polymerase III 
3 
 
Table 2 Score system of the classification in SSc - from van den Hoogen F at al Arthritis 
Rheum. 2013 
34
. 
 
The total score is determined by adding the maximum weight (score) in each 
category. Patients with a total score of ˃9 are classified as having definite SSc. 
In our population, we also consider the major subsets of SSc: 
- Limited cutaneous SSc: defined by skin thickening in areas solely distal to the 
elbows and knees, with or without facial effects, such as telangiectases. 
- Diffuse cutaneous SSc: patients have skin thickening over both proximal and 
distal limbs, as well as the face and the trunk. Reduction in the oral aperture is 
common. 
1.3 Cardiac manifestations of the SSc 
 
Cardiac manifestation of SSc is particularly problematic in the clinical practice. In 
the majority of patients, cardiac manifestations are subclinical. Systolic and/or 
diastolic dysfunction can develop very early in the course of the disease, even years 
before becoming clinically evident. Cardiac involvement is common in SSc, with an 
estimated clinical prevalence of 15–35% while at post-mortem examination the heart 
was affected in up to 80% of the patients 
5
 
6
.  The development of overt myocardial 
manifestations is recognized as powerful adverse prognostic factors and may affect 
patients with both limited cutaneous SSc and diffuse cutaneous SSc. When clinically 
evident, these features are often associated with increased mortality 
5
 
6 7 8. All cardiac 
structures: the endocardium, myocardium, pericardium, valves, coronary arteries, 
electrical and autonomic nervous system, may be involved, potentially leading to 
14 
 
heart failure. Primary myocardial involvement, without systemic or PAH and without 
significant renal or pulmonary involvement, implicates different pathophysiological 
mechanisms, including the characteristic vascular lesions and fibrosis deposition, 
which may impair coronary microcirculation and myocardial function.  
Myocardial fibrosis is a hallmark of cardiac manifestation of SSc. In SSc the 
myocardium is often characterized by patchy fibrosis, secondary to both repeated 
ischemia and/or immuno-inflammatory damage, inexorably leading to myocardial 
dysfunction. In SSc, the cause of ischemia is usually not the consequence of the 
epicardial coronary artery stenosis, but rather to microvascular dysfunction 
35
.  
Characteristic vascular lesions in SSc result in the impairment of the microcirculation 
9
.  In addition to these fixed abnormalities, vasospasm of the small coronary arteries 
or arterioles may play a significant role in the development of early myocardial 
alterations 
36
. Furthermore, diastolic dysfunction is frequent in SSc 
37
 
38
 
39
, and is 
correlated with disease duration 
40
, whereas systolic dysfunction is present in only a 
minority of patients 
41
. Myocardial fibrosis in SSc can affect both ventricles, leading 
to increased ventricular mass, decreased movement of the ventricular walls and 
impaired relaxation of myocardial tissue during diastole 
7
 
37
.    
 
1.4  Pulmonary manifestations of the SSc 
 
Pulmonary involvement is a prominent feature of the SSc and occurs more frequently 
in SSc than in any other connective tissue disease 
42
. The two most frequent types of 
lung involvement are ILD and pulmonary arterial hypertension (PAH) 
43
. SSc-related 
PAH is the result of an isolated pulmonary arteriopathy, but in these patients, 
elevated PAP may occur also as a consequence of ILD or LV systolic and/or 
diastolic dysfunction, a condition that should be more generically addressed as PH, 
not as PAH.  The diagnosis of PAH is established during right heart catheterization 
(RHC), when mean pulmonary arterial pressure (mPAP) exceeds 25 mmHg with a 
pulmonary capillary wedge pressure (PCWP) below 15 mmHg 44. Additional 
diagnostic criteria may include normal or reduced cardiac output (CO) or a 
pulmonary vascular resistance (PVR) over 3 Wood units
45
. 
PAH is a severe vascular complication of the SSc and it has a dramatic impact on the 
clinical course and overall survival of the patients. It is the single most common 
cause of death in patients affected by this syndrome. The prevalence of 
15 
 
hemodynamically proven PAH in large cohorts of patients with SSc was about 5% to 
10% 
46
 
47
. The three-year survival for SSc patients with PAH has been estimated to 
be 56% compared with 94% in those without PAH 48. Observational studies have 
demonstrated that mortality remained high in SSc patients with PAH even when new 
therapeutic options (new drugs, new methods) were applied 
49
 
50
 
51
 
52
 (Figure 2).  
 
 
Figure 2 Kaplan–Meier analysis showing the survival in patients with SSc-related 
pulmonary arterial hypertension (SSc-PAH) and idiopathic pulmonary arterial 
hypertension treated with prostanoids or advanced therapy.  Fisher MR at al Arthritis 
Rheum 2006 51, Kawut SM at all, Chest 2003 52 
 
Markers of worse prognosis include male gender, late age at diagnosis, pericardial 
effusion, functional severity based on the New York Heart Association (NYHA) 
functional class, right heart dysfunction, and hyponatremia 49 52. Poor outcome of 
PAH in SSc may be partially explained by disease-related co-morbidities but also by 
a delay in diagnosis. Signs and symptoms of SSc-PAH are generally aspecific, and 
thus often underestimated. The establishment of the diagnosis is frequently delayed 
to the advanced phases of the pathological process, characterized by structural and 
not reversible damage of the pulmonary vasculature. RHC is the criterion standard 
for PAP measurement. However, RHC is not applicable to large populations because 
of its invasive nature and costs. This is another reason why PAH is usually 
recognized at advanced stages, when the treatment does not significantly change the 
clinical course of the disease 52 53. Therefore, efforts to promote an early recognition 
of PAH have been expended in the last few years 
46
. One recent study observed 
16 
 
better prognosis in subjects identified in an active screening program compared with 
those identified in the course of routine practice 
54
 suggesting a potential benefit of 
the intervention earlier in the course of disease (Figure 3). 
 
Figure 3 Prognosis for PAH-SSc patients detected in routine practice or via a 
screening program Humbert M at al. Eur Respir Rev. 2012 54  
 
 
The subsequent important issue is the presence of an associated ILD in patients with 
SSc. ILD is a common and serious form of pulmonary involvement is SSc and 
characterized by various patterns of inflammation and fibrosis on high-resolution CT 
scan and in lung biopsy specimen (Figure 4). ILD was an important prognostic factor 
in patients with SSc and PAH 
49 55 56. SSc patients with ILD-associated PAH have a 
worse prognosis. However, ILD either limited or extensive, even without PAH, also 
has an impact on the overall prognosis, and ILD is also one of the leading causes of 
death in SSc 11 57. Patients with limited SSc disease will typically develop isolated 
PAH 10 to 15 years after the onset of their disease 
58
. In contrast, patients with 
diffuse SSc are at greater risk for ILD, usually within the first 5 years after the 
establishment of the diagnosis when the most rapid rate of decline in forced vital 
capacity is observed, but PAH may develop at any stage in the course of their 
disease. Although PAH is generally modest (mPAP 25–35 mmHg) in patients with 
ILD, PAP elevations can be more substantial. 
17 
 
 
 
Figure 4 shows pulmonary fibrosis in high resolution computed tomography scan and 
in a lung specimen. 
Courtesy; Robert C Mellors, M.D. PhD. Immunopathology, 1995 
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2. Primary goals of the thesis  
 
Considering the fact that cardiac and pulmonary manifestations are very frequent in 
SSc leading to rapid progression of the disease and to fatal outcome in a substantial 
number of the patients, it is essential to recognize the early signs of these 
manifestations. Therefore, our goals of the present research were: 
 
1. To assess whether two dimensional speckle tracking echocardiography (STE) 
parameters may detect early alterations in left atrial (LA) function in SSc patients. 
 
2. To evaluate the clinical and echocardiographic determinants of exercise-
induced increase in pulmonary artery systolic pressure (PASP) in a large population 
of patients with SSc. 
 
3. To evaluate whether the exercise-induced PASP increase may predict resting 
PASP increase in a population of SSc patients. 
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3. Methods  
 
3.1. Patient selection 
 
For the study of the early involvement of the LA function, from September 2009 to 
January 2010, 42 consecutive patients affected by SSc (Group 1, age 50 ± 14 years, 
95% females), admitted to the Department of Rheumatology in Florence, and 42 age 
and gender-matched control subjects (Group 2, age 49 ± 13 years, and 95% females) 
were enrolled. Patients in Group 1 underwent a thorough clinical assessment, 
pulmonary function test 
59
, assessment of pulmonary fibrosis by standard chest X-
ray, lung ultrasound 
60
, when clinically indicated, by thoracic high-resolution 
computed tomography scan 
61
. Inclusion criteria were: 1) age > 18 and < 85 years; 2) 
a previous diagnosis of SSc according to the European Scleroderma Trial and 
Research (EUSTAR) recommendations 
62
. Exclusion criteria were: 1) inability to 
provide informed consent; 2) known history of coronary artery disease, 
electrocardiographic signs of myocardial ischemia, LV ejection fraction <55%, 
regional wall motion abnormalities, LV hypertrophy, more than mild valvular heart 
disease, pericardial effusion, and evidence or clear history of atrial fibrillation, or 
inadequate LA tracking for strain analysis. Anticentromere antibodies (ACA by 
indirect immunofluorescence on Hep-2 cells and by ELISA for CENP antigen) and 
antitopoisomerase I antibodies (anti-Scl70 by immunoblot analysis) were 
determined. All operators were unaware of the results of the other tests. The local 
Ethical Committee of Pisa, Italy, protocol number 2849, approved the study, and all 
patients gave informed consent. For the exercise echo study, from May 2007 to June 
2009, 220 patients with SSc admitted to the Department of Rheumatology in 
Florence (n = 53), Milan (n = 76), Pisa (n = 47), Potenza (n = 5), Szeged (n = 9), and 
Udine (n = 30) underwent a thorough clinical and instrumental assessment, according 
to the European Scleroderma Trial and Research (EUSTAR) recommendations 
62
. 
Inclusion criteria were as follows: 1) age ≤18 and ≥85 years and 2) a previous 
diagnosis of SSc according to the American Rheumatism Association classification 
criteria. Exclusion criteria were as follows: 1) inability to provide informed consent 
and 2) known history of coronary artery disease, more than mild valvular heart 
disease, and evidence or clear history of atrial fibrillation. All operators were 
20 
 
unaware of the results of the other tests. The Ethical Committee of Pisa approved the 
protocol (no. 2849), and all patients gave informed consent.  The selection process is 
depicted in Figure 5. 
 
 
Figure 5 Flowchart showing patient selection process. 
 
37 SSc patients (age = 58±13 years, 82% females, 74% limited cutaneous form) with 
normal resting PASP (<40 mmHg), who had developed exercise-induced PASP 
increase at a previously graded bicycle semi-supine exercise Doppler 
echocardiography (EDE). They underwent the same examination after at least six 
months. Patients having had a resting PASP > 40 mmHg did not perform the 
exercise. The average follow-up period was 21 ± 12 months.  
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3.2.  The role of echocardiography in the assessment of cardiac and   
pulmonary manifestations of systemic sclerosis 
 
Echocardiography is crucial in the evaluation of patients affected by SSc because it 
makes it possible to detect not only cardiac abnormalities responsible for the 
symptoms but subclinical dysfunctions as well. Echocardiography is also frequently 
used in vasculitis to assess valvular abnormalities, hypertension-related damage, 
sequelae of vasculitis related ischemia, and of course, systolic and diastolic 
functions. A main limitation of echocardiography is that ejection fraction is often the 
only parameter provided to evaluate cardiac function, whereas more subtle 
myocardial dysfunction cannot be assessed. Several studies have recently proposed 
novel echocardiographic techniques such as Tissue Doppler Imaging (TDI) and STE 
as effective tools for early detection of right and LV systolic and diastolic 
dysfunction 
63
. 
Echocardiography is routinely employed in SSc for the screening of PAH, although 
right heart catheterization is necessary for proper diagnostic confirmation. Exercise 
Doppler echocardiography could be useful for the screening and the understanding of 
the pathophysiological mechanisms leading to PAH in patients with SSc. In the 
present research, we employed new echocardiographic techniques and methods – 
detailed below – for the evaluation of early cardiac manifestation of SSc.  
3.2.1.  New techniques to assess myocardial involvement 
Strain describes myocardial deformation and appears in the fractional change in the 
length of the myocardial segment. Strain is usually expressed as a percentage.  Strain 
rate imaging is a relatively new, largely angle-independent technique used for the 
detailed evaluation of myocardial function. The speckles seen in grayscale B-mode 
images are the result of constructive and destructive interference of ultrasound 
backscattered from structures. With this technology, random noise is filtered out, 
while keeping small temporally stable and unique myocardial features referred to as 
speckles. Blocks or kernels of speckles can be tracked from frame to frame 
(simultaneously in multiple regions within an image plane) using block matching, 
and provide local displacement information from which parameters of myocardial 
function such as velocity, strain, and strain rate can be assessed 
64
. Assessment of 2D 
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strain by STE can be applied to both ventricles and atria and it provides 
sophisticated, detailed information about myocardial function in SSc.  
3.2.2.  Detailed methodological description of the LA study  
All patients underwent comprehensive two-dimensional transthoracic 
echocardiography examinations at rest, using conventional methods with a 
commercially available ultrasound machine (Vivid 7, GE Medical Systems, Horten, 
Norway) equipped with a 2.5–3.5 MHz phased array sector scan probe, second 
harmonic technology, and coupled with tissue TDI. LV end-diastolic and end-
systolic diameters were measured from the internal dimensions obtained from 
parasternal long axis view. LA diameters were measured from the apical four-
chamber view. LA areas and volumes were measured using the biplane method of 
disks (modified Simpson’s rule), in the apical 4- and 2-chamber view at end-systole 
(maximum LA size), and a mean value of area and volume was obtained 
65
. LA 
volumes were subsequently indexed to body surface area (BSA). LV mass was 
calculated by the Devereux formula and then indexed to body surface area 
65
. Mitral 
regurgitation was assessed semi-quantitatively (0 = absent or trivial, 1 = mild, 2 = 
moderate, 3 = severe), including evaluation of vena contracta, regurgitant volume 
and effective regurgitant orifice area, when indicated 
66
. TDI was evaluated, as 
previously described, in the pulsed-wave Doppler mode, to assess longitudinal 
myocardial regional LV function. A volume was sampled centrally to the basal 
segment of infero-septal and antero-lateral wall for the LV, and then the mean value 
of the velocity profiles was recorded. Gain and filters were adjusted as needed, to 
eliminate background noise and to obtain a clear tissue signal. TDI signals were 
recorded at a sweep of 100 mm/s. Each parameter was measured as the average of at 
least three consecutive beats. LV diastolic function was determined from the pattern 
of mitral flow velocity by pulsed Doppler echocardiography, complemented by 
mitral annular velocity by TDI and LA volumes 
67
. PASP was estimated from peak 
tricuspid regurgitation jet velocities, adding right atrial pressure estimated from 
inferior vena cava diameter and respiratory changes 
68
. All measurements were 
performed according to the recommendations of the European Association of 
Echocardiography/ American Society of Echocardiography 65 66 67 68. 
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Assessment of the left atrial function 
Particular attention was paid to obtaining an adequate grayscale image, allowing 
reliable delineation of myocardial tissue and extracardiac structures. During breath 
hold, 3 consecutive heart cycles were recorded and averaged. The frame rate was set 
between 60 and 80 frames per second. These settings are recommended to combine 
temporal resolution with adequate spatial definition, and to enhance the feasibility of 
the frame-to-frame tracking technique 
69
. 
 Recordings were processed by using an acoustic-tracking software (EchoPac PC 
version 108.1.4, GE Healthcare, Horten, Norway), allowing off-line semi-automated 
analysis of STE strain. In the end-diastolic/systolic frame, the atrial endocardial 
border was traced by a point-and-click method. After automatic creation of a region 
of interest, the LA wall was divided into six subregions, and segmental tracking 
quality was analyzed. We analyzed LA from apical two- and four-chamber views, so 
we used a 12-segment model. The dashed curve represents the average strain (Figure 
5). The tracking settings allow distinguishing three LA strain values. If the reference 
point is set at the onset of the QRS, we can measure positive peak atrial longitudinal 
strain (ε pos peak), which corresponds to LA reservoir function (Figure 5). If the 
reference point is set at the onset of the P wave, we can measure both negative atrial 
longitudinal strain (ε neg peak), which mirrors LA pump function and second 
positive peak atrial strain (sec ε pos peak), which corresponds to LA conduit function 
(Figure 6). Inter- and intra-observer variability of strain parameters has been 
previously assessed 
70
.  
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Figure 5 2D speckle tracking derived LA peak, positive longitudinal strain (ε pos peak)  
measurement form apical 4 chamber view ( the reference point is the beginning of 
the QRS complex).  
 
 
 
Figure 6 Measurement of second positive peak longitudinal LA strain ( sec ε pos peak) 
and negative peak  longitudinal strain (ε neg peak) from apical four chamber view ( the 
reference point is the onset of the p wave).  
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3.2.3.  Methods of the exercise echo study 
All patients underwent a comprehensive transthoracic echocardiogram using 
conventional methods with commercially available ultrasound devices (Sonos 7500 
and IE33 [Philips Medical Systems, Andover, MA], Sequoia C256 Acuson [Siemens, 
Mountain View, CA], Famiglia Mylab25 [Esaote, Genoa, Italy], Vivid System 7 
[GE/Vingmed, Milwaukee, WI]) equipped with 2.5- to 3.5-MHz phased array 
transducers, second harmonic technology, and coupled with TDI. Pulmonary artery 
systolic pressure was derived from the maximal velocity of tricuspid Doppler tracing 
(TRV) according to the Bernoulli equation and adding the value of right atrial 
pressure, estimated on the basis of collapsibility index of the inferior vena cava 
68
. 
Stroke volume, CO and cardiac index (CI) assessments were performed by the LV 
outflow track Doppler method. PVR was estimated by the following formula: 
TRV/RVOT (right ventricular outflow tract) time velocity integral × 10 + 0.16 71. 
PCWP was noninvasively derived by the following formula: PCWP = (1.24 × [E/e′]) 
+ 1.9, where E/e′ represents peak early diastolic velocity to early diastolic velocity at 
basal mitral annulus ratio 72, and mPAP was calculated as 0.6 × PASP + 2 73. We 
measured the ratio PASP/CI to normalize pulmonary pressure increases for increases 
in CO 
74 75.  
All measurements were performed according to the recommendations of the 
European Association of Echocardiography (EAE)/American Society of 
Echocardiography 65. 
Exercise stress echo was conducted using a graded semisupine bicycle ergometer 
with 25-W incremental loading every 2 minutes 
76
. A 12-lead electrocardiogram and 
a blood pressure measurement were performed at baseline and every minute 
thereafter. Transthoracic 2-dimensional echocardiographic monitoring was 
performed throughout and up to 5 minutes after the end of stress. Tricuspid Doppler 
tracing and RVOT time-velocity integral were estimated at peak exercise, while the 
patient was still pedaling. Immediately after that, while the patient was stopping 
pedaling, LV outflow track time-velocity integral and measurements of left and RV 
function were performed because PASP and CO return rapidly back to normal after 
exercise, although it is less relevant for CO 77. A cutoff value of PASP ≥50 mmHg at 
peak exercise was considered a significant exercise-induced increase in PASP. A 
cutoff value of peak PVR ≥3.0 Wood Units (WU) was considered a significant PVR 
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increase 
68
. The stress test was symptom limited. Criteria for test positivity and 
terminating the test followed EAE recommendations 
76
. 
Quality control  
Almost all echocardiographic examinations (90%) were performed by the same 
operator (G.A.). The remaining examinations were performed by operators with long 
experience in echocardiography, who passed the quality control in stress 
echocardiography, as previously described 
78
. This resulted in homogeneous data and 
image acquisition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
4. Statistical analysis 
Data are presented as mean ± standard deviation (SD) unless otherwise stated. 
Comparisons between SSc patients and controls in the LA study were performed by 
using Student’s t-tests or by non-parametric Mann-Whitney U-test, as appropriate. 
Comparisons between categorical variables were made with χ2 test. All tests were 
two-sided, and p-values < .05 were considered statistically significant. Correlations 
were tested by Pearson or Spearman’s correlation tests, as appropriate. Univariate 
comparisons between patients with and without exercise induced increase in PASP 
were made with χ2, 2-sample t test or similarly Mann-Whitney U test, as appropriate. 
The association of selected variables with the development of exercise-induced 
increase in PASP and PVR was assessed by logistic regression analysis using 
univariate and stepwise multivariate procedures. The following variables were 
included into the analysis: age, gender, body mass index, diffuse form, Scl-70 
antibody positivity, Raynaud’s phenomenon, Rodnan skin score, ILD, pulmonary 
function test data, resting echocardiographic parameters (ejection fraction, wall 
motion score index, indexed LV and LA volumes, Tricuspid Annular Plane Systolic 
Excursion (TAPSE), TDI systolic LV and RV waves, E/e′, RV tricuspid annulus 
early to late diastolic velocity ratio [E′/A′], PASP, acceleration time, CI, PCWP), 
stress echocardiographic parameters (peak wall motion score index, peak CI, peak 
MAPSE, peak TAPSE, peak TDI systolic LV and RV wave), peak workload, and 
peak oxygen saturation. Variables were selected according to their clinical relevance 
and potential impact on PASP and/or PVR, as shown by earlier studies. Categorical 
variables are presented as counts and percentages. All analyses were performed by 
using SPSS 20.0.0.0 (IBM Inc, Chicago, IL, USA) and GraphPad Prism version 6 
(GraphPad Software Inc., San Diego, CA, USA). 
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5.  Results 
 
 5.1. Results of the LA study 
 
The clinical and echocardiographic characteristics of Groups 1 and 2 are summarized 
in Tables 3 and 4. From the initial population of 55 patients, 7 were excluded for 
inadequate LA tracking quality, and 6 were excluded for the evidence of cardiac 
abnormalities (2 patients for EF<55%, 3 patients for pericardial effusion, 1 patient 
for LV hypertrophy) (Figure 5).  
The two groups did not differ in systolic function of the LV (Group 1 EF = 63.1±4%, 
vs. Group 2 = 66.1±4%, p=ns).  SSc patients did not show significantly different LA 
indexed volumes (Group 1 = 24.9  5.3 ml/m
2 
vs. Group 2 = 24.7 4.4 ml/m
2
, p = .8) 
(Figure 7), but showed significantly different LV diastolic and LA longitudinal strain 
parameters. E/e’ ratio was higher in SSc patients (Group 1 = 7.6±2.4 vs. Group 2 = 
6.5±1.7, p˂.05, Figure 8) and ε pos peak and sec ε pos peak were significantly decreased 
(Group 1 = 31.3  4.2% vs. Group 2 = 35.0  7.6%, p < .01 and Group 1 = 18.4  4 
% vs. Group 2 = 21.4  7.6%, p < .05) (Figure 9).  ε neg peak did not show significant 
differences (Group 1 = 12.9  2% vs. Group 2 = 13.6  3%, p=ns). Interestingly, we 
found significant correlation between ε pos peak and age, but only in the control group 
(R = -.59, p < .001) and not in SSc patients (R = -.09, p = .57). Among 
echocardiographic parameters, no correlations were found between LA ε pos peak and 
LV EF, nor E/e’, or LA indexed volume or PASP. No significant difference in LA ε 
pos peak values were found between patients with and without Scl-70 antibodies (31.1 ± 
4.2 vs. 30.6 ± 4.1, p =.75). No echocardiographic, STE or clinical parameter was 
different between patients in NYHA class I and NYHA classes II–III, including 
diffusing capacity of carbon monoxide (DLCO). 
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Table 3 Clinical characteristics 
Clinical variables 
Group 
1 
(SSc) 
42 pts 
Group 2 
(Controls) 
42 pts 
p 
Age (years) 
50 ± 
14 
49 ± 13 ns 
Female gender 
(n,%) 
40 
(95%) 
40 (95%) ns 
Systemic arterial 
hypertension (n,%) 
10 
(24%) 
16 (38%) ns 
Diabetes (n,%) 
0 
(0%) 
1 (2%) ns 
History of Smoking 
(n,%) 
3 
(7%) 
6 (14%) ns 
Limited form n (%) 
35 
(83%) 
  
Diffuse form n (%) 
7 
(17%) 
  
Scl-70 antibodies 
n(%) 
13 
(31%) 
  
DLCO (%) 
80.6 ± 
23.2 
  
NTpro-BNP (pg/ml) 
122 ± 
135 
  
SSc: systemic sclerosis 
DLCO: diffusing capacity of carbon monoxide. 
NTpro-BNP: N-terminal B-type natriuretic peptide 
Table 4 Echocardiographic data 
Echo variables 
Group 1 
(SSc) 
42 pts 
Group 2 
(Controls) 
42 pts 
p 
EF (%) 63.1±4 66.1±4 ns 
LA indexed 
volumes(ml/m
2
) 
24.9±5.3 24.7±4.4 ns 
E/A 1.1±0.4 1.3±0.4 ns 
E/e’ 7.6±2.4 6.5±1.7 p˂0.05 
PASP(mmHg) 24.1±8 21±7 ns 
sec ε pos peak 
(%)   
18.4±4 21.4±7.6 p˂0.05 
ε neg peak  (%) 12.9±2 13.6±3 ns 
ε pos peak (%) 31.3±4.2 35±7.6 p˂0.01 
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ε pos peak: positive peak left atrial longitudinal strain; sec ε pos peak: second positive peak left atrial 
longitudinal strain; ε neg peak – negative peak left atrial longitudinal strain; A: mitral inflow late pulsatile 
Doppler wave; E: mitral inflow early pulsatile Doppler wave; e': early diastolic mitral annular 
velocity; EF: ejection fraction; LA: left atrium; PASP: pulmonary artery systolic pressure; SSc: 
systemic sclerosis.   
 
 
Figure 7   Differences in the indexed left atrial volume between SSc and control 
patients. 
 
 
 
Figure 8  Differences in E/e’ between SSc and control patients. 
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Figure 9 Differences in peak positive LA longitudinal strain (ε pos peak) between SSc 
and control patients. 
 
5.2. Results of the exercise echo study 
 
From 220 patients, 22 were excluded: 13 for inadequate echocardiographic image 
quality, 5 for inability to perform physical activity, 3 for previously unknown cardiac 
conditions, and 1 for resting dyspnea (NYHA class III). In thirteen patients, tricuspid 
regurgitation signal was present, and measurement of TRV was not measurable both 
at rest and/or at peak stress (feasibility 93%), and 21 patients were excluded because 
resting PASP was high, above 40 mmHg (Figure 5). Specification of the remaining 
164 patients is shown in Table 6.  
 
Male, n (%)  14 (8.5) 
Age (y)  58 ± 13 
NYHA class II, n (%) 57 (35) 
Years since diagnosis  11 ± 9 
Diabetes mellitus, n (%)  6 (4) 
Hypertension, n (%)  39 (24) 
Diffuse form, n (%)  41 (25) 
Scl-70 antibodies, n (%)) 41 (25 
NT-proBNP (ng/L)  144 ± 160 
FEV1/VC (%)  94 ± 13 
DLCO (%)  70 ± 19 
 
Table 6 Clinical characteristics of patients 
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During stress test no major, serious complications occurred. No patients had 
ischemic positive test considering ECG and echo criteria. 
Exercise echo results 
Among the 164 patients who underwent EDE study, 69 (42%) patients showed a 
PASP at peak exercise ≥50 mmHg. Mean peak TRV was 332 cm/s (range 185–533 
cm/s). 
Changes in PASP characteristics from rest to peak exercise for individual patients are 
shown in Figure 10. 
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Figure 10 Changes in PASP measurements from rest to peak exercise for each 
individual patient. 
 
Table 7 represents the different characteristics between patients with peak PASP < 
50 and ≥50 mmHg. Univariate analysis showed that age, presence of ILD, values of 
resting PASP, and both right and left diastolic dysfunctions were predictors of PASP 
elevation over ≥50 mmHg (Table 8). According to observation, peak PASP was 
higher in patients older than 50 years (52 ± 14 mmHg vs. 43 ± 8 mmHg, p˂ .001), 
with LV E/e′ ˃8 (59 ± 17 mmHg vs. 48 ± 13 mmHg,  p˂ .01), with RV E′/A′ ˂0.8 
33 
 
(52 ± 11 mmHg vs 44 ± 9 mmHg, p˂ .001), and with ILD (54 ± 14 mmHg vs. 48 ± 
12 mmHg, p˂ .05). 
 
 
 Peak 
PASP˂50 
mmHg 
(n = 95) 
Peak 
PASP≥50  
mmHg 
(n = 69) 
p 
value 
Ejection fraction 
(%) 
65± 6 66 ± 6  NS 
Wall motion score 
index 
1 ± 1 1 ± 1 NS 
LV end-diastolic 
volume/BSA 
(mL/m2) 
51 ± 11 52 ± 11 NS 
LV end-systolic 
volume/BSA 
(mL/m2) 
16 ± 7 16 ± 6  NS 
Left atrium 
volume/BSA 
(mL/m2) 
24 ± 8 27 ± 12 NS 
E/e′ 6.6 ± 2.0 7.5 ± 2.6 ˂.05 
TAPSE (mm) 22 ± 4 21 ± 3 NS 
RV TDI peak 
systolic velocity 
14 ± 4 14 ± 3 NS 
Acceleration time 
(ms) 
124 ± 29 106 ± 34 ˂.01 
RV E′/A′ 0.96 ± 0.35 0.72 ± 0.16 ˂.001 
CI (L min−1 m−2) 2.5 ± 0.6 2.7 ± 0.8 NS 
PCWP (mm Hg) 10 ± 2 11 ± 3 ˂.05 
PVR (WU) 1.7± 0.4 1.7 ± 0.3 NS 
 
Table 7 Differences in resting echocardiographic data between patients with peak 
PASP ˂50 mmHg and those with peak PASP ≥50 mmHg. 
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 Peak 
PASP˂50 
mmHg 
(n = 95) 
Peak 
PASP≥50  
mmHg 
(n = 69) 
p 
value 
TAPSE (mm) 26 ± 4 26 ± 4 NS 
RV TDI peak 
systolic velocity 
21 ± 6 22 ± 7 NS 
Acceleration time 
(ms) 
98 ± 22 85 ± 27 ˂.05 
PCWP (mmHg) 10 ± 2 11 ± 3 ˂.05 
PVR (WU) 2.0 ± 0.7 2.3± 0.6 ˂.05 
Systolic arterial 
pressure (mmHg) 
157 ± 24 168 ± 20 ˂.01 
Heart rate 138 ± 21 129 ± 16 ˂.01 
Oxygen saturation 
(%) 
97 ± 4 97 ± 3 NS 
Test performance 
(W) 
79 ± 26 72 ± 24 NS 
Test duration (min) 5.8 ± 2.0 5.4 ± 1.8 NS 
mPAP/CO (mm Hg 
L−1 min−1) 
3.1 ± 2.7 6.5 ± 5.5 ˂.001 
 
 
Table 8 Differences in stress echocardiographic data between patients with peak 
PASP ˂50 mmHg and those with peak PASP ≥50 mmHg. 
       Univariate analysis Multivariate analysis 
        HR (95% CI)              
                         p value 
           HR (95% CI)               
                               p value 
     
Age (y)  1.06 (1.03-1.09) ˂.001  1.03(0.94-1.12) NS 
Raynaud’s 
phenomenon 
0.56(0.23-1.7) NS   
Diffuse 
form 
1.24 (0.61-2.5) NS   
ILD 2.3(1.01-5.3) ˂.05 0.7 (0.9-5.4) NS 
DLCO (%) 0.99 (0.97-1.01) NS   
Resting 
PASP (mm 
Hg) 
1.2 (1.1-1.3)                
˂.001 
1.2 (1.1-1.3)             ˂.05 
E/e′ 1.19 (1.01-1.4) ˂.05 0.9 (0.5-1.8)               NS 
RV E′/A’ 0.03 (0.003-0.36) ˂.01 0.25 (0.002-0.4)             ˂.01 
Peak CI (L 
min−1 m−2) 
1.1 (0.86-1.5) NS   
 
Table 9 Univariate and multivariate analysis to predict peak PASP ≥50 mmHg. 
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In a subgroup of 89 patients, noninvasive hemodynamic parameters were also 
measured (PVR, CO). Feasibility of the acquisition was 95% at rest and 73% at peak 
stress. Peak PVR ≥3 WU was present in 11% of patients with peak PASP ≥50 
mmHg, which represents about 5% of the total population. Univariate analysis 
showed that none of the parameters predictors of peak PASP ≥50 mmHg were 
predictors of PVR ≥3 WU (Table 9). Pressure/flow relationship in this subgroup is 
shown in Figure 11. The mPAP/CO ratio was 4.9 ± 4.7 mmHg L−1 min−1. The 
mPAP/CO ratio did not correlate with age, LV diastolic dysfunction, or ILD but 
correlated with RV diastolic dysfunction (expressed by TDI E′/A′, R = −0.33, p˂ 
.05). 
 
 
Figure 11 Pressure/Flow relationship at rest and at peak stress. Patients with peak 
PVR ≥3 WU are highlighted by dotted lines. 
 
5.3. Results of the follow up study 
Mean follow-up time between the two EDE was 21 ± 12 months, during which two 
deaths occurred. Seven patients (19%) developed resting PASP increase (mean time 
follow-up 22 ± 15 months), which may suggest that the previous abnormal response 
to exercise in these patients predicted subclinical PAH. Twenty-four patients (65%) 
showed the same behavior as at a previous examination, 2 patients (7%) had died, 
and 4 patients (11%) did not confirm the exercise-induced PASP increase, with 3 
patients having started calcium-antagonist therapy. The figurative results are shown 
in Table 12. 
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Figure 12 PASP characteristics of 37 patients during follow up stress 
echocardiography study. 
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6.  Discussion 
 
6.1.  Discussion of the LA study 
 
Our results suggest that SSc patients with normal LV systolic function and without 
any significant cardiac abnormalities have reduced LA STE values compared to the 
control group. STE may be a non-invasive, feasible method to assess early LA 
dysfunction in SSc patients. Such cardiac mechanic alterations can be detected in the 
absence of changes in LA size.  
Pathophysiological mechanisms of LA dysfunction in SSc 
LA is a reservoir, a conduit and a pump, which plays an important role in modulating 
LV filling 79 80. According to the Frank-Starling law, LA pump function increases in 
the presence of mild LV diastolic dysfunction and then significantly decreases when 
LV diastolic dysfunction progresses to moderate or severe degrees 
80
 
79
 
81
. Global LA 
function parameters such as LA dimensions, area and volume are good prognostic 
markers for predicting LV diastolic dysfunction 
82
 
83
.  However, an impairment of 
these parameters may appear late in the course of the disease. STE provides early, 
detailed information about LA mechanics. Several studies have demonstrated the 
usefulness of STE in assessing LA function 
84
 
85
 
86
 
87
, Inaba Y et al. have shown that 
LA strain rate correlate with age, LA size and diastolic dysfunction in patients with 
atrial fibrillation 85. LA strain rate was also an accurate predictor of recovery of LA 
contractility after cardioversion 
86
, and LA ε pos peak was a significant predictor of 
postoperative atrial fibrillation in patients undergoing aortic valve replacement 87. 
In SSc, the myocardium is often characterized by patchy fibrosis, secondary to both 
repeated ischemia and/or immuno-inflammatory damage, inexorably leading to 
diastolic dysfunction. Episodes of ischemia in SSc are usually not due to epicardial 
coronary artery stenosis, but rather to microvascular dysfunction
35
 since 
characteristic SSc vascular lesions result in major impairment of the microcirculation 
9
. In addition to these fixed abnormalities, vasospasm of the small coronary arteries 
or arterioles may play a significant role in the early myocardial alterations in SSc 
36
. 
Diastolic dysfunction is frequent in SSc 
37 38 39 and is correlated with the duration of 
the disease
40
, whereas systolic dysfunction is present in only a minority of SSc 
38 
 
patients 
41
. Myocardial fibrosis in SSc has been reported in 50–80% of necropsy 
series 
88
 
89
 
90
 
91
 
92
 
93
 
94
, however, establishing the diagnosis of myocardial fibrosis can 
be challenging by non-invasive imaging. Up-to-now MRI has been considered to be  
the non-invasive gold standard imaging technique to assess myocardial fibrosis. 
Previous studies have observed high percentages of myocardial fibrosis at MRI 
through detection of late gadolinium enhancement, although with different 
prevalence 
88
 
89
 
90
 
91
 
92
 
93
 
94
 (95–101). In a recent study, Ntusi et al. 95 have  found 
that although biventricular size and global function are preserved, there is 
impairment in the peak systolic circumferential and peak diastolic strain rate of the 
LV, which inversely correlates with diffuse myocardial fibrosis indices at MRI.  
Clinical implications 
Characterization of the LA has important prognostic implications 
96
 
97
. LA 
enlargement is known to be associated with increased mortality in the general 
population 
83
. Impaired LA function might also be an important predictor for the 
development of non-valvular atrial fibrillation or other supraventricular arrhythmias 
98
, which are not infrequent in SSc patients. In our population, no patients had atrial 
fibrillation or other significant supraventricular arrhytmia. It would be interesting to 
see whether LA dysfunction can predict the development of supraventricular 
arrhythmia in this population. In our study, the LA reservoir (ε pos peak) and conduit 
(sec ε pos peak) function are impaired compared to controls. We may suspect that 
myocardial involvement and changes in the ECM may lead to early dysfunction of 
LA, even before the LA starts to dilate, since there was no difference between LA 
volume in the two groups. Early alternations of LA function can also reflect LV 
involvement in SSc. Myocardial fibrosis and consequent LV diastolic dysfunction 
leads to the decrease of LA reservoir and conduit function and to the increase of LA 
pump function (Frank-Starling law). The clinical meaning of an early assessment of 
LA mechanism in SSc by STE is still undetermined, and follow-up studies with a 
larger number of patients are needed to evaluate whether this finding has any 
prognostic implication. However, the use of a non-invasive, non-ionizing, and 
relatively simple method that lets us track LA function characteristics over time is 
intriguing. Speckle tracking allows a very sensitive estimation and monitoring of LA 
mechanism that may help us understand the progressive steps in the ongoing 
pathophysiological process leading to overt myocardial dysfunction. STE 
measurement has been demonstrated to correlate also with the extent of LA fibrosis 
39 
 
and remodeling 
99
. This new echocardiographic analysis of LA function might also 
be employed as a biomarker in therapeutic trials to assess efficacy in serial 
evaluations and follow-up of new therapeutic options. 
Comparison with previous studies  
To the best of our knowledge, this is the first study evaluating LA function in SSc by 
STE strain analysis. Several reports have previously described subclinical LV and 
RV abnormalities in SSc patients, using TDI parameters and strain rate imaging
38
 
39, 
100
 
101
 
102
 
103
 
104
 
105
. Mele et al. have shown that TDI-derived myocardial systolic 
deformation indices, based on strain and strain rate analysis and E/e’ ratio, are 
valuable approaches to detecting cardiac involvement in asymptomatic SSc patients 
39. D’Andrea et al. have further confirmed that STE imaging can detect both RV and 
LV early myocardial involvement in SSc, as well as coronary flow reserve and 
brachial artery flow-mediated dilatation, as signs of early vascular impairment
103
. In 
another study, Shattke et al. have employed isovolumetric acceleration, a novel tissue 
Doppler parameter, to detect early RV systolic impairment in SSc patients without 
PAH 
101
. Kepez et al. have found that SSc patients without PAH and overt clinical 
cardiac involvement have reduced myocardial strain and strain rate, despite normal 
2D, conventional Doppler and TDI parameters 
100
 . Interestingly, Yiu et al. have 
revealed that subtle LV dysfunction, still assessed by STE strain analysis, is related 
to lower functional capacity and rhythm disturbances in patients with SSc 
104
. 
Recently, Spethmann et al. have highlighted that LV systolic impairment, as assessed 
by strain imaging, is primarily due to alterations in the basal LV segments in SSc 
patients with preserved LVEF 
105
. All previous studies on speckle tracking in SSc 
patients have never addressed LA function or dimensions, because they focus on LV 
or RV function. It is true that assessment of both left and right ventricular 
dysfunction is the main target of cardiac assessment and represents the final result of 
all potential pathophysiological impairments. However, many of these alterations can 
be intercepted earlier by means of changes of the LA region mechanical 
characteristics and function. A few previous studies have evaluated LA 
characteristics in SSc patients: Dimitroulas et al. have shown that LA volume may be 
a useful non-invasive marker for the prediction of elevated PAP in these patients 
106
.  
Impairment of electromechanical LA functions, including a prolonged intra-
interatrial electromechanical delay and higher P-wave dispersion have also been 
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found in SSc patients, compared to a control group, confirming the increased risk of 
these patients for developing supraventricular arrhythmias 
106
. 
  
Study limitations  
Some limitations of the present study should be highlighted. The study population 
was limited in size, since SSc is a relatively rare disease. Additionally, we excluded 
patients with signs of overt cardiac involvement, which could have affected strain 
and strain rate measurements. 
Therefore, our results cannot be extended to patients with heart failure or other 
concomitant cardiac disease. Finally, the study population was relatively old. It is 
well known that the occurrence of diastolic dysfunction increases with age. However, 
age was not different in the two groups, and interestingly, we found significant 
correlation between ε pos peak and age only in the control group and not in SSc 
patients. A main limitation was the lack of normal cut-off values for strain imaging. 
However, two studies report LA strain values in a healthy population, which can be 
considered as reference values 
70 107 108. 
Although very promising, a current significant limitation of strain imaging is inter-
vendor variability; thus, up-to-date, strain analysis is still confined to the research 
field and has not yet been implemented in routine clinical practice 
 
6.2.  Discussion of the EDE study  
 
Exercise-induced increase in PASP is frequent in patients with SSc and seems to be 
related to many factors affecting diastolic LV and RV function, whereas exercise 
induced increase in PVR is less frequent and not related to these parameters. Non-
invasive hemodynamic evaluation by EDE has an established role in valvular heart 
disease, diastolic heart failure. Exercise induced PAH is still a poorly understood 
entity in patients at risk for developing PAH. It is controversial whether it could be 
considered an early preclinical functional phase, inexorably leading to resting PAH 
53
. The recent American and European Guidelines reflect this conflict: the definition 
of exercise-induced PAH, always present in the past guidelines, has been abandoned 
because it is “not supported by enough published data”. However, exercise 
echocardiography is “supported by an objective interest and should be used in a 
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research setting”. Actually, in the past few years, many reports on the use of exercise 
test both with RHC and EDE in different diseases
109
, 
110
 (78–81,102,103) 111, 112 113 
114 115  athletes75, or healthy volunteers have been published 116. There are concordant 
data from different study groups about a significant percentage of patients with SSc 
with an abnormal increase of PASP at peak exercise 
111
 
112
 
117
. However, there is 
consensus that the prevalence of apparently inappropriate pulmonary pressure 
response to exercise is too high, occurring in about 50% patients, whereas the 
incidence of PAH in this population is only about 5% to 10%. Our multicenter study 
with quite large population confirms these previous reports. Because peak PASP is 
also determined by the physiological increase in pulmonary output
75
 
118
, normalizing 
PASP for CI may reduce the incidence of false-positive results. Abnormal increase in 
PASP can be secondary to pulmonary abnormalities
119
, therefore, careful history 
taking and other investigations should be obtained to identify the presence of ILD. 
Pulmonary artery systolic pressure is also influenced by the diastolic feature of LV - 
high LV filling pressures, which may be consequent to LV; thus, all parameters 
affecting LV diastolic function, such as age 
120 121 122 or systemic arterial 
hypertension, may potentially influence peak PASP. The increase in PCWP with 
exercise is remarkable in healthy older subjects and may be responsible for PAP 
values ˃40 mmHg122. Similarly in our population, both resting and peak PASPs were 
significantly higher in patients older than 50 years. Cardiac involvement, LV 
myocardial fibrosis, which is not infrequent in SSc plays a role and determines 
diastolic dysfunction. All these significant influences may explain why peak PASP 
does not necessarily represent the best parameter to identify the subgroup of patients 
likely to develop resting PAH. When we consider a parameter less affected by other 
conditions such as PVR, the number of patients with an abnormal increase in PVR at 
peak stress is significantly lower, accounting for about 5% of the initial study group, 
a percentage consistent with the reported prevalence of hemodynamically proven 
PAH in large cohorts of patients with SSc 
46
. Pulmonary involvement may also lead 
to an increase in PVR. In our population, the presence of ILD did not predict high 
peak PVR, probably because the degree of pulmonary involvement was never severe, 
and because this information is somehow part of RV diastolic function evaluation. 
However, in patients with significant ILD, PASP and PVR should not be considered 
as reliable indices of early PAH because the increase in both parameters may be 
caused by different pathophysiological basis. Our data are similar to a recently 
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published article of D'Alto M at al 
74
. In this work, the authors underline that caution 
is necessary in interpreting the results of EDE in patients with SSc because an 
abnormal pulmonary vascular reserve might be related to the presence of mild to 
moderate ILD or to subtle signs of LV diastolic dysfunction. Moreover, they 
underline that the RV E’/A’ ratio was lower in patients with SSc than in control 
subjects. Our data show that resting RV E’/A’ ratio is a determinant of exercise-
induced increase in PASP, although it could be debated whether this early alteration 
in the diastolic function is more likely to be the cause or the consequence of exercise-
induced increase in PASP. Clinical implications of the present work are of 
importance because it exhorts to a more conscious use of EDE in patients at high risk 
for developing PAH. It is now quite clear that peak PASP is not enough to 
characterize these patients and that a more thorough hemodynamic evaluation, 
together with an accurate history taking and clinical assessment, is mandatory.  RHC 
remains the reference standard for clinicians to set up the diagnosis and establish the 
indication to start appropriate, PAH specific therapies, but the procedure is 
unfortunately not without morbidity and cannot be routinely proposed. Our study 
outlines that heterogeneous hemodynamic mechanisms may underlie the same 
phenotypic markers of exercise-induced PASP increase. Diastolic dysfunction caused 
by primary myocardial involvement or other determinants and primary inappropriate 
increase in pulmonary resistance have different underlying causes, heterogeneous 
hemodynamic mechanisms and conceivably different therapeutic and prognostic 
correlates. The different mechanisms may coexist and overlap in the individual 
patient and also have a variable role in different stages of the disease. Some 
limitations of the present study should be highlighted. The cutoff value of 50 mmHg 
to identify an abnormal exercise-induced PASP is arbitrary because no established 
cutoff exists. We chose this value to be as specific as possible to identify patients 
with an abnormal vascular response. It seems based on previous studies that there 
might be a bimodal distribution of exercise-induced PASP, with a second peak at 
about 50 mmHg that is more likely to identify patients reacting to exercise in a 
different and possibly pathological way 
74
 
115
 (76,110).  Non-invasive measurement 
of PVR is an indirect evaluation, and although a good correlation has been shown 
with invasive values 
123
 
124
  Doppler-derived PVR is not universally acknowledged as 
a reliable non-invasive surrogate for PVR. Moreover, previous studies have already 
used non-invasive PVR evaluation at peak exercise, 119 125 but the formula has been 
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validated only at rest 
71
. Inferior vena cava diameter and collapsibility index to 
estimate right atrial pressure were not reassessed at peak exercise, possibly leading to 
PASP underestimation. 
6.3.  Discussion of the follow-up study 
Although exercise testing (including EDE) has not been included to the recent 
guidelines about PAH, our preliminary results suggest that exercise stress 
echocardiography may play a role in the diagnostic evaluation of PAH in patients 
with SSc. In the pulmonary vasculature, more than 70% of the vascular bed is lost 
before the pressure reaches the pathological level at rest
126
. The exact mechanisms of 
increased PAP during exercise are unknown. However, they are likely to be due, at 
least in part, to the early stages of endothelial dysfunction and vascular remodeling in 
the pulmonary circulation that may have little initial effect at rest but become more 
evident during exercise. From a pathophysiological point of view, pulmonary artery 
systolic pressure under physical exercise depends mainly on the inability of the SSc 
pulmonary vascular bed to dilate and consequently would reflect the peculiar stiff 
vascular system characteristic of SSc
127
. From a clinical point of view, our data 
suggest that this inability, when exceeding a defined value, is predictive for the 
development of symptomatic PH during the follow-up. With EDE the identification 
of patients susceptible to future PAH has already been studied. However, the data are 
conflicting. Data from the UK national registry of CTD-PAH showed that ~20% of 
SSc patients with exercise during right heart catheterization (mean PAP >30 mmHg) 
progressed to PAH requiring advanced therapy within 3 years
49
. Moreover, Steen et 
al.
114
 have demonstrated that EDE unmasked PAH in a substantial number of 
scleroderma population at increased risk for PAH (DLCO<60% predictive, forced 
vital capacity (FVC)/DLCO>1.6 and estimated systolic PAP 30–50 mmHg). In this 
study, 44% of the patients had an increase of >20 mmHg in right ventricular systolic 
pressure on echocardiography during exercise. These patients then underwent RHC 
and 62% were found to have elevated pressures. Dehnert C et al. have studied 
individuals susceptible to high altitude pulmonary edema in normal sea level using 
hypoxia and EDE in combination. Their study demonstrates that EDE in normoxia is 
sufficient to detect individuals susceptible to high altitude pulmonary edema
128
. 
Additionally, Gruenig et al.
115
 have shown that exercise elevation of pulmonary 
44 
 
pressures is more common among first degree relatives of individuals with familial 
PAH, and in some probands progression to overt PAH has been observed.  
In contrast, a study by Codullo et al.
129
 using EDE and follow-up in a low-risk 
scleroderma population (asymptomatic without overt PAH; tricuspid regurgitation 
velocity <3 m/s-¹) have found that only one in 19 patients developed PAH requiring 
advanced therapy when using an increase in systolic PAP of ≥18 mmHg after 
exercise as the criteria 
74
. However, this study has analyzed a different patient 
population (low risk, versus intermediate and high risk in our study), and the 
conclusion has been drawn after the analysis of a very small patient population.   
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7.  New observations 
 
1. 2D speckle-tracking echocardiography is a sensitive tool to assess impairment of 
LA mechanics, which is detectable in the absence of changes in LA size and volume, 
and may represent an early sign of cardiac involvement in patients with SSc. 
 
2.   Exercise-induced increase in PASP occurs in almost half of the patients with SSc 
with normal resting PASP. Peak exercise PASP is affected by age, ILD, and right 
and LV diastolic dysfunction, and only in 5% of the patients, it is associated with an 
increase in PVR during exercise, suggesting heterogeneity of the mechanisms 
underlying exercise-induced PAH in SSc.                              
3. EDE is a feasible test to track serial changes over time in PASP in patients at high 
risk of developing PAH. Exercise-induced PASP increase is frequently associated 
with poor outcome or development of overt resting PASP increase. 
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